{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:00:50Z","timestamp":1790809250034,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41409-024-02363-7","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T12:01:55Z","timestamp":1720785715000},"page":"1413-1422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-9353","authenticated-orcid":false,"given":"Jaehyun","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9131","authenticated-orcid":false,"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daehun","family":"Kwag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi June","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-4136","authenticated-orcid":false,"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-2050","authenticated-orcid":false,"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-6616","authenticated-orcid":false,"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-3366","authenticated-orcid":false,"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-4839","authenticated-orcid":false,"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9442-9814","authenticated-orcid":false,"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"2363_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMra052638","volume":"354","author":"EA Copelan","year":"2006","unstructured":"Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813\u201326. https:\/\/doi.org\/10.1056\/NEJMra052638","journal-title":"N Engl J Med"},{"key":"2363_CR2","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR3","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.bbmt.2011.02.011","volume":"17","author":"S Santarone","year":"2011","unstructured":"Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, et al. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Transpl. 2011;17:1505\u201311. https:\/\/doi.org\/10.1016\/j.bbmt.2011.02.011.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR4","doi-asserted-by":"publisher","first-page":"e812","DOI":"10.1097\/hs9.0000000000000812","volume":"7","author":"A Spyridonidis","year":"2023","unstructured":"Spyridonidis A, Labopin M, Savani B, Giebel S, Bug G, Sch\u00f6nland S, et al. Reduced 8-gray compared to standard 12-gray total body irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a study of the acute leukemia working party of the EBMT. Hemasphere. 2023;7:e812. https:\/\/doi.org\/10.1097\/hs9.0000000000000812.","journal-title":"Hemasphere"},{"key":"2363_CR5","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","volume":"106","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N, Kroger N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \u201cwhen and for whom\u201d in 2021? Haematologica. 2021;106:1794\u2013804. https:\/\/doi.org\/10.3324\/haematol.2020.268839.","journal-title":"Haematologica"},{"key":"2363_CR6","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114\u201325. https:\/\/doi.org\/10.1038\/s41409-020-0803-y.","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood-2007-08-104745","volume":"112","author":"R Marks","year":"2008","unstructured":"Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood. 2008;112:415\u201325. https:\/\/doi.org\/10.1182\/blood-2007-08-104745.","journal-title":"Blood"},{"key":"2363_CR8","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41409-023-01966-w","volume":"58","author":"K Hirschbuhl","year":"2023","unstructured":"Hirschbuhl K, Labopin M, Polge E, Blaise D, Bourhis JH, Socie G, et al. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2023;58:874\u201380. https:\/\/doi.org\/10.1038\/s41409-023-01966-w.","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41409-020-01050-7","volume":"56","author":"S Giebel","year":"2021","unstructured":"Giebel S, Labopin M, Sobczyk-Kruszelnicka M, Stelljes M, Byrne JL, Fegueux N, et al. Total body irradiation + fludarabine compared to busulfan + fludarabine as \u201creduced-toxicity conditioning\u201d for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2021;56:481\u201391. https:\/\/doi.org\/10.1038\/s41409-020-01050-7.","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR10","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395:1146\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(19)33018-1","journal-title":"Lancet"},{"key":"2363_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.bbmt.2014.04.021","volume":"20","author":"F Malard","year":"2014","unstructured":"Malard F, Chevallier P, Guillaume T, Delaunay J, Rialland F, Harousseau JL, et al. Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution\u2019s three decade experience. Biol Blood Marrow Transpl. 2014;20:1217\u201323. https:\/\/doi.org\/10.1016\/j.bbmt.2014.04.021.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR12","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/s41409-020-0878-5","volume":"55","author":"Z Peric","year":"2020","unstructured":"Peric Z, Labopin M, Peczynski C, Polge E, Cornelissen J, Carpenter B, et al. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT. Bone Marrow Transpl. 2020;55:1560\u20139. https:\/\/doi.org\/10.1038\/s41409-020-0878-5.","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR13","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.bbmt.2018.11.016","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Alahdab F, Firwana B, Sonbol MB, Almader-Douglas D, Palmer J. Choosing a reduced-intensity conditioning regimen for allogeneic stem cell transplantation, fludarabine\/busulfan versus fludarabine melphalan: a systematic review and meta-analysis. Biol Blood Marrow Transpl. 2019;25:728\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2018.11.016.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/cncr.31874","volume":"125","author":"JH Yoon","year":"2019","unstructured":"Yoon JH, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. Cancer. 2019;125:873\u201383. https:\/\/doi.org\/10.1002\/cncr.31874.","journal-title":"Cancer"},{"key":"2363_CR15","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/ajh.23465","volume":"88","author":"KS Eom","year":"2013","unstructured":"Eom KS, Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol. 2013;88:634\u201341. https:\/\/doi.org\/10.1002\/ajh.23465.","journal-title":"Am J Hematol"},{"key":"2363_CR16","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/leu.2012.164","volume":"26","author":"S Lee","year":"2012","unstructured":"Lee S, Kim DW, Cho BS, Yoon JH, Shin SH, Yahng SA, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26:2367\u201374. https:\/\/doi.org\/10.1038\/leu.2012.164.","journal-title":"Leukemia"},{"key":"2363_CR17","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdw123","volume":"27","author":"JH Yoon","year":"2016","unstructured":"Yoon JH, Yhim HY, Kwak JY, Ahn JS, Yang DH, Lee JJ, et al. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Oncol. 2016;27:1081\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw123","journal-title":"Ann Oncol"},{"key":"2363_CR18","doi-asserted-by":"publisher","first-page":"7650","DOI":"10.1002\/cam4.2680","volume":"8","author":"JH Yoon","year":"2019","unstructured":"Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer Med. 2019;8:7650\u20139. https:\/\/doi.org\/10.1002\/cam4.2680.","journal-title":"Cancer Med"},{"key":"2363_CR19","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41409-019-0708-9","volume":"55","author":"SY Yoon","year":"2020","unstructured":"Yoon SY, Yoon JH, Min GJ, Park SS, Park S, Lee SE, et al. Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2020;55:1469\u201372. https:\/\/doi.org\/10.1038\/s41409-019-0708-9.","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12185-021-03231-6","volume":"115","author":"SH Lee","year":"2022","unstructured":"Lee SH, Yoon JH, Min GJ, Park SS, Park S, Lee SE, et al. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. Int J Hematol. 2022;115:135\u20139. https:\/\/doi.org\/10.1007\/s12185-021-03231-6.","journal-title":"Int J Hematol"},{"key":"2363_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231154713","volume":"14","author":"JH Yoon","year":"2023","unstructured":"Yoon JH, Kwag D, Lee JH, Min GJ, Park SS, Park S, et al. Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score-matched cohort analysis. Ther Adv Hematol. 2023;14:20406207231154713 https:\/\/doi.org\/10.1177\/20406207231154713.","journal-title":"Ther Adv Hematol"},{"key":"2363_CR22","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","volume":"116","author":"M Mohty","year":"2010","unstructured":"Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439\u201343. https:\/\/doi.org\/10.1182\/blood-2010-02-266551.","journal-title":"Blood"},{"key":"2363_CR23","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/j.bbmt.2017.09.003","volume":"23","author":"K Kawamura","year":"2017","unstructured":"Kawamura K, Kako S, Mizuta S, Ishiyama K, Aoki J, Yano S, et al. Comparison of conditioning with fludarabine\/busulfan and fludarabine\/melphalan in allogeneic transplantation recipients 50 years or older. Biol Blood Marrow Transpl. 2017;23:2079\u201387. https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.003.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR24","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41409-020-01097-6","volume":"56","author":"JH Yoon","year":"2021","unstructured":"Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Impact of donor type on long-term graft-versus-host disease-free\/relapse-free survival for adult acute lymphoblastic leukemia in first remission. Bone Marrow Transpl. 2021;56:828\u201340. https:\/\/doi.org\/10.1038\/s41409-020-01097-6.","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Prim. 2023;9:27 https:\/\/doi.org\/10.1038\/s41572-023-00438-1.","journal-title":"Nat Rev Dis Prim"},{"key":"2363_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41577-020-00457-z","volume":"21","author":"E Velardi","year":"2021","unstructured":"Velardi E, Tsai JJ, van den Brink MRM. T cell regeneration after immunological injury. Nat Rev Immunol. 2021;21:277\u201391. https:\/\/doi.org\/10.1038\/s41577-020-00457-z.","journal-title":"Nat Rev Immunol"},{"key":"2363_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41409-023-02139-5","volume":"59","author":"A Spyridonidis","year":"2024","unstructured":"Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2024;59:217\u201323. https:\/\/doi.org\/10.1038\/s41409-023-02139-5.","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR28","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/sj.leu.2404886","volume":"21","author":"A Shimoni","year":"2007","unstructured":"Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine\/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine\/busulfan. Leukemia. 2007;21:2109\u201316. https:\/\/doi.org\/10.1038\/sj.leu.2404886.","journal-title":"Leukemia"},{"key":"2363_CR29","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1038\/s41375-021-01277-3","volume":"35","author":"NJ Short","year":"2021","unstructured":"Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 2021;35:3044\u201358. https:\/\/doi.org\/10.1038\/s41375-021-01277-3.","journal-title":"Leukemia"},{"key":"2363_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrclinonc.2017.176","volume":"15","author":"DT Teachey","year":"2018","unstructured":"Teachey DT, Hunger SP. Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm. Nat Rev Clin Oncol. 2018;15:69\u201370. https:\/\/doi.org\/10.1038\/nrclinonc.2017.176.","journal-title":"Nat Rev Clin Oncol"},{"key":"2363_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/asheducation-2015.1.215","volume":"2015","author":"MR van den Brink","year":"2015","unstructured":"van den Brink MR, Velardi E, Perales MA. Immune reconstitution following stem cell transplantation. Hematol Am Soc Hematol Educ Program. 2015;2015:215\u20139. https:\/\/doi.org\/10.1182\/asheducation-2015.1.215","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2363_CR32","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1182\/blood-2013-11-539031","volume":"124","author":"A Mensen","year":"2014","unstructured":"Mensen A, Johrens K, Anagnostopoulos I, Demski S, Oey M, Stroux A, et al. Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT. Blood. 2014;124:963\u201372. https:\/\/doi.org\/10.1182\/blood-2013-11-539031.","journal-title":"Blood"},{"key":"2363_CR33","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jcyt.2023.05.012","volume":"25","author":"AG Troullioud Lucas","year":"2023","unstructured":"Troullioud Lucas AG, Lindemans CA, Bhoopalan SV, Dandis R, Prockop SE, Naik S, et al. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis. Cytotherapy. 2023;25:977\u201385. https:\/\/doi.org\/10.1016\/j.jcyt.2023.05.012.","journal-title":"Cytotherapy"},{"key":"2363_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1615\/CritRevImmunol.2016017507","volume":"36","author":"M Kuczma","year":"2016","unstructured":"Kuczma M, Ding ZC, Zhou G. Immunostimulatory effects of melphalan and usefulness in adoptive cell therapy with antitumor CD4+ T cells. Crit Rev Immunol. 2016;36:179\u201391. https:\/\/doi.org\/10.1615\/CritRevImmunol.2016017507","journal-title":"Crit Rev Immunol"},{"key":"2363_CR35","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.bbmt.2015.01.019","volume":"21","author":"HT Kim","year":"2015","unstructured":"Kim HT, Armand P, Frederick D, Andler E, Cutler C, Koreth J, et al. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transpl. 2015;21:873\u201380. https:\/\/doi.org\/10.1016\/j.bbmt.2015.01.019.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR36","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3324\/haematol.2011.059378","volume":"97","author":"B Federmann","year":"2012","unstructured":"Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3\/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica. 2012;97:1523\u201331. https:\/\/doi.org\/10.3324\/haematol.2011.059378.","journal-title":"Haematologica"},{"key":"2363_CR37","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.bbmt.2011.10.039","volume":"18","author":"D Pastore","year":"2012","unstructured":"Pastore D, Delia M, Mestice A, Carluccio P, Perrone T, Gaudio F, et al. CD3+\/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transpl. 2012;18:887\u201393. https:\/\/doi.org\/10.1016\/j.bbmt.2011.10.039.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR38","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1172\/JCI129965","volume":"130","author":"SJ Divito","year":"2020","unstructured":"Divito SJ, Aasebo AT, Matos TR, Hsieh PC, Collin M, Elco CP, et al. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest. 2020;130:4624\u201336. https:\/\/doi.org\/10.1172\/JCI129965","journal-title":"J Clin Invest"},{"key":"2363_CR39","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7:e157\u2013e167. https:\/\/doi.org\/10.1016\/S2352-3026(19)30256-X","journal-title":"Lancet Haematol"},{"key":"2363_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3324\/haematol.2016.148510","volume":"102","author":"F Baron","year":"2017","unstructured":"Baron F, Mohty M, Blaise D, Soci\u00e9 G, Labopin M, Esteve J, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:224\u201334. https:\/\/doi.org\/10.3324\/haematol.2016.148510.","journal-title":"Haematologica"},{"key":"2363_CR41","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","volume":"55","author":"F Bonifazi","year":"2020","unstructured":"Bonifazi F, Rubio MT, Bacigalupo A, Boelens JJ, Finke J, Greinix H, et al. Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transpl. 2020;55:1093\u2013102. https:\/\/doi.org\/10.1038\/s41409-020-0792-x.","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR42","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/s41409-022-01666-x","volume":"57","author":"R Massoud","year":"2022","unstructured":"Massoud R, Klyuchnikov E, Gagelmann N, Zabelina T, Wolschke C, Ayuk F, et al. Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation. Bone Marrow Transpl. 2022;57:1548\u201355. https:\/\/doi.org\/10.1038\/s41409-022-01666-x.","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR43","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.bmt.1705648","volume":"39","author":"C Heining","year":"2007","unstructured":"Heining C, Spyridonidis A, Bernhardt E, Schulte-Monting J, Behringer D, Grullich C, et al. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. Bone Marrow Transpl. 2007;39:613\u201322. https:\/\/doi.org\/10.1038\/sj.bmt.1705648.","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR44","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1182\/blood.V90.8.3204","volume":"90","author":"GR Hill","year":"1997","unstructured":"Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JLM. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204\u201313. https:\/\/doi.org\/10.1182\/blood.V90.8.3204","journal-title":"Blood"},{"key":"2363_CR45","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1182\/blood.V80.12.2964.2964","volume":"80","author":"JH Antin","year":"1992","unstructured":"Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964\u20138. https:\/\/doi.org\/10.1182\/blood.V80.12.2964.2964","journal-title":"Blood"},{"key":"2363_CR46","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/sj.bmt.1703230","volume":"28","author":"JE Johansson","year":"2001","unstructured":"Johansson JE, Brune M, Ekman T. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transpl. 2001;28:737\u201342. https:\/\/doi.org\/10.1038\/sj.bmt.1703230","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR47","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.bbmt.2016.07.006","volume":"22","author":"N Kekre","year":"2016","unstructured":"Kekre N, Marquez-Malaver FJ, Cabrero M, Pinana J, Esquirol A, Soiffer RJ, et al. Fludarabine\/busulfan versus fludarabine\/melphalan conditioning in patients undergoing reduced-intensity conditioning hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transpl. 2016;22:1808\u201315. https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.006.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR48","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12185-021-03233-4","volume":"115","author":"Y Yamada","year":"2022","unstructured":"Yamada Y, Ikegawa S, Najima Y, Atsuta Y, Konuma R, Adachi H, et al. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine\/low-dose melphalan plus 4 Gy TBI versus fludarabine\/ busulfan plus 4 Gy TBI. Int J Hematol. 2022;115:244\u201354. https:\/\/doi.org\/10.1007\/s12185-021-03233-4.","journal-title":"Int J Hematol"},{"key":"2363_CR49","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","volume":"19","author":"UD Bayraktar","year":"2013","unstructured":"Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:344\u201356. https:\/\/doi.org\/10.1016\/j.bbmt.2012.08.011.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR50","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.bbmt.2017.03.035","volume":"23","author":"JL Pi\u00f1ana","year":"2017","unstructured":"Pi\u00f1ana JL, Perez-Pitarch A, Garcia-Cadenas I, Barba P, Hernandez-Boluda JC, Esquirol A, et al. A time-to-event model for acute kidney injury after reduced-intensity conditioning stem cell transplantation using a tacrolimus- and sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transpl. 2017;23:1177\u201385. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.035.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR51","doi-asserted-by":"publisher","unstructured":"Vergara-Cadavid J, Johnson PC, Kim HT, Yi A, Sise ME, Leaf DE et al. Clinical features of acute kidney injury in the early post-transplantation period following reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2023. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.029","DOI":"10.1016\/j.jtct.2023.03.029"},{"key":"2363_CR52","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","volume":"15","author":"SO Ciurea","year":"2009","unstructured":"Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2009;15:523\u201336. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.489.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR53","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","volume":"8","author":"A Kashyap","year":"2002","unstructured":"Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, et al. Intravenous versus oral busulfan as part of a busulfan\/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transpl. 2002;8:493\u2013500. https:\/\/doi.org\/10.1053\/bbmt.2002.v8.pm12374454","journal-title":"Biol Blood Marrow Transpl"},{"key":"2363_CR54","first-page":"6203","volume":"50","author":"G Vassal","year":"1990","unstructured":"Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990;50:6203\u20137.","journal-title":"Cancer Res"},{"key":"2363_CR55","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41375-018-0185-y","volume":"32","author":"JA Fein","year":"2018","unstructured":"Fein JA, Shimoni A, Labopin M, Shem-Tov N, Yerushalmi R, Magen H, et al. The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia. 2018;32:1787\u201394. https:\/\/doi.org\/10.1038\/s41375-018-0185-y.","journal-title":"Leukemia"},{"key":"2363_CR56","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/bmt.2015.278","volume":"51","author":"X Cahu","year":"2016","unstructured":"Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Soci\u00e9 G, et al. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transpl. 2016;51:351\u20137. https:\/\/doi.org\/10.1038\/bmt.2015.278.","journal-title":"Bone Marrow Transpl"},{"key":"2363_CR57","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.bbmt.2018.09.042","volume":"25","author":"GL Chen","year":"2019","unstructured":"Chen GL, Hahn T, Wilding GE, Groman A, Hutson A, Zhang Y, et al. Reduced-intensity conditioning with fludarabine, melphalan, and total body irradiation for allogeneic hematopoietic cell transplantation: the effect of increasing melphalan dose on underlying disease and toxicity. Biol Blood Marrow Transpl. 2019;25:689\u201398. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.042.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02363-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02363-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02363-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T12:02:34Z","timestamp":1728043354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02363-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2363"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02363-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the Catholic University of Korea (reference number: KC24RISI0192). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}